MD Buyline identifies top emerging technologies with highest impact

Jul 15 2010

MD Buyline recently identified the top emerging technologies with the highest impact for 2010 as:

• Autologous Cell Therapy
• Alzheimer's Therapeutic Drug
• Sepsis Microfilter
• Non-Invasive Cardiac Radiosurgery

This release will explain how these important technologies encourage high utilization rates across multiple service lines, bringing value to hospitals. Reimbursement changes and hospital structure enable technology purchases to generate a sequence of changes throughout service lines and dramatically impact the bottom line. Here's how:

Autologous Cell Therapy: Five million patients are affected by congestive heart failure annually. No therapies are available other than full heart transplant to repair damaged heart tissue. Autologous cell therapy utilizes a patient's own cells for the treatment of damaged myocardium. Once approved, the therapy will replace technology for heart transplants, life-long drug therapy, and ICDs for heart muscle repair. This therapy offers potential to replace a whole range of supportive cardiovascular therapies.

Alzheimer's Therapeutic Drug: Alzheimer's is projected to reach epidemic proportions by the year 2015. Current therapies exclusively help manage the symptoms of the disease. Researchers recently identified the cause of the disease, allowing them to develop a potential cure with the second-generation Alzheimer's therapeutic drug PBT2. PBT2 is designed to prevent and promote clearing of amyloidal plaque deposits in the brain. High-end imaging such as PET and SPECT will see an increase in usage in order to confirm the diagnosis of Alzheimer's disease.

Sepsis Microfilter: Sepsis is the second leading cause of death in non-coronary critical care patients and 10^th overall COD. The initial treatment of Septic shock consists of a combination of antibiotics and fluid replacement. Time is critical to the survival rate of the patient because there is a significant time lapse before the drug therapy takes effect. The Sepsis microfilter device is intended to rapidly clear the blood of pathogens to help prevent the organs from shutting down while waiting for the drug therapy to take effect.

Non-invasive Cardiac Radiosurgery: This technique provides a non-invasive, more time-efficient alternative to catheter-based technology, using the robotic linear accelerator from Accuray®, the CyberKnife®. The technology uses radiation generated from outside the patient to target regions of the heart, forming lesions around the pulmonary vein. Once approved, CyberHeart offers the security of a fully-automated robotic technology capable of delivering reproducible results.